Miglustat Accord

Miglustat, the active ingredient in Miglustat Accord, is a glucosylceramide synthase inhibitor presented as an oral tablet for oral use. It is used to treat rare lysosomal storage disorders such as Niemann‑Pick disease type C and Gaucher disease type 1 in appropriate patients.

GNH USA supplies Miglustat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres, oncology centres and clinics worldwide.

Miglustat is a substrate reduction therapy that targets the accumulation of glycosphingolipids in lysosomal storage disorders. - Niemann‑Pick disease type C: slows neurological decline and improves survival outcomes. - Gaucher disease type 1: reduces spleen and liver volume and improves hematologic parameters.

Miglustat may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling of stomach upset. - Flatulence: increased intestinal gas. - Weight loss: unintended reduction in body weight. - Tremor: mild shaking of hands or limbs. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas requiring immediate medical attention. - Severe hypersensitivity: rash, swelling, or difficulty breathing. - Liver enzyme elevation: significant increase in hepatic transaminases. - Depression or mood changes: new or worsening psychiatric symptoms.

Before initiating therapy, clinicians should assess patient-specific factors and monitor for potential complications. - Liver function monitoring: check transaminases regularly. - Blood glucose assessment: monitor for hypoglycemia, especially in diabetic patients. - Gastrointestinal tolerance: evaluate for persistent diarrhea or weight loss. - Renal impairment: adjust use in patients with reduced kidney function. - Hypersensitivity screening: avoid in individuals with known allergy to miglustat. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Miglustat can interact with several drug classes, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase miglustat plasma levels. - Concomitant antidiabetic agents: heightened risk of hypoglycemia. - Other substrate reduction therapies: additive toxicity risk.

Moderate Interactions (Monitor Closely): - Moderate CYP inducers (e.g., rifampicin): may reduce miglustat effectiveness. - Antacids containing aluminum or magnesium: can affect gastrointestinal absorption. - Warfarin: may require INR monitoring due to potential interaction.